Journal of the American Academy of Dermatology
Volume 62, Issue 4 , Pages 655-662 , April 2010

Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation

  • Misha Rosenbach, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Sylvia Hsu, MD

      Affiliations

    • Department of Dermatology, Baylor College of Medicine, Houston, Texas
    • ,
  • Neil J. Korman, MD, PhD

      Affiliations

    • Department of Dermatology and the Murdough Family Center for Psoriasis, Case Western Reserve University/University Hospital of Cleveland, Cleveland, Ohio
    • ,
  • Mark G. Lebwohl, MD

      Affiliations

    • Department of Dermatology, Mount Sinai School of Medicine, New York University, New York, New York
    • ,
  • Melodie Young, ARNP

      Affiliations

    • Modern Dermatology, Dallas, Texas
    • ,
  • Bruce F. Bebo Jr., PhD

      Affiliations

    • National Psoriasis Foundation, Portland, Oregon
    • ,
  • Abby S. Van Voorhees, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • Corresponding Author InformationReprint requests: Abby S. Van Voorhees, MD, Hospital of the University of Pennsylvania, 2 Rhoads, 3400 Spruce St, Philadelphia, PA 19104.

,Accepted 14 May 2009.

References 

  1. Boyd AS, Menter A. Erythrodermic psoriasis: precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21:985–991
  2. Goeckerman WH, O'Leary PA. Erythrodermic psoriaticum: a review of twenty-two cases. JAMA. 1932;99:2102–2105
  3. Marks J. Erythrodermas and uric acid aberrations in psoriasis. In: Farber EM, Cox AJ, editors. Psoriasis: proceedings of the international symposium. Stanford: Stanford University Press; 1971. p. 89–98.
  4. Rym BM, Mourad M, Bechir Z, Calenda E, Faika C, Iadh AM, et al. Erythroderma in adults: a report of 80 cases. Int J Dermatol. 2005;44:731–735
  5. Morar N, Dlova N, Gupta AL, Naidoo DK, Aboobaker J, Ramdial PK. Erythroderma: a comparison between HIV positive and negative patients. Int J Dermatol. 1999;38:895–900
  6. Burton JL, Rook A, Wilkinson DS. Eczema, lichen simplex, erythroderma and prurigo. In:  Rook A,  Wilkinson DS,  Ebling FJG editor. Textbook of dermatology. 4th ed. Boston: Blackwell; 1986;p. 367–418
  7. Abrahams I, McCarthy JT, Sanders SL. 101 Cases of exfoliative dermatitis. Arch Dermatol. 1963;87:96–101
  8. Prystowsky JH, Cohen PR. Pustular and erythrodermic psoriasis. Dermatol Clin. 1995;13:757–770
  9. Van Der Vleuten CJM, Gerritsen MJP, Steijlen PM, de Jong EM, van de Kerkhof PC. A therapeutic approach to erythrodermic psoriasis: report of a case and a discussion of therapeutic options. Acta Derm Venereol. 1996;76:65–67
  10. Shekelle PG, Woolf SH, Eecles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593–596
  11. Baker H, Ryan TJ. Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases. Br J Dermatol. 1968;80:771–793
  12. Yen A. Comment on: Arbiser et al, Use of short-course class I topical glucocorticoid under occlusion for the rapid control of erythrodermic psoriasis. Arch Dermatol. 1995;131:227
  13. Sehgal VN, Srivastava G, Sardana K. Erythroderma/exfoliative dermatitis: a synopsis. Int J Dermatol. 2004;43:39–47
  14. Berth Jones J, Bourke J, Baily K, Graham Brown RA, Hutchinson PE. Generalized pustular psoriasis: response to topical calcipotriol. BMJ. 1992;305:868–869
  15. Green MS, Prystowsky JH, Cohen SR, Cohen JI, Lebwohl MG. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol. 1996;34:911–914
  16. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Management of erythrodermic psoriasis with low-dose cyclosporine. Dermatology. 1993;187:30–37
  17. Poulalhon N, Begon E, Lebbe C, Liote F, Lahfa M, Bengofa D, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156:329–336
  18. Koo J. Lee J. Cyclosporine: what clinicians need to know. Dermatol Clin. 1995;13:897–907
  19. Rongioletti F, Broenstein M, Kirsner R, Kerdel F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatol Treat. 2003;14:222–225
  20. Takahashi MDF, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007;157:828–831
  21. Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica. 1988;176:182–190
  22. Ling MR. Acitretin: optimal dosing strategies. J Am Acad Dermatol. 1999;41(Suppl):S13–S17
  23. Ahdout J, Mandel H, Chiu M. Erythroderma in a patient taking acitretin for plaque psoriasis. J Drugs Dermatol. 2008;7:391–394
  24. Collins P, Rogers S. The efficacy of methotrexate in psoriasis–a review of 40 cases. Clin Exp Dermatol. 1992;17:257–260
  25. van Dooren-Greebe RJ, Kuijpers AL. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol. 1994;130:204–210
  26. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382–388
  27. Esposito M, Mazzotta A. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006;155:156–159
  28. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50:416–430
  29. Heikkila H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005;141:1607–1610
  30. Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with cyclosporin and infliximab. Br J Dermatol. 2003;149:170–173
  31. Korstanje MJ, Bessems PJ, van de Staak WJ. Combination therapy ciclosporin-etretinate effective in erythrodermic psoriasis. Dermatologica. 1989;179:94
  32. Kokelj F, Plozzer C, Torsello P, Trevisan G. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports). J Eur Acad Dermatol Venereol. 1998;11:177–179
  33. Brechtel B, Wellenreuther U, Toppe E, Czarnetski BM. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. J Am Acad Dermatol. 1994;30:1023–1024
  34. Kuijpers ALA, van Dooren-Greebe RJ, van de Kerkhof PCM. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis. Dermatology. 1997;194:88–90
  35. Aydin F, Canturk T, Senturk N, Turanli AY. Methotrexate and cyclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol. 2006;31:520–524
  36. Korstanje MJ, van Breda Vriesman CJP, van de Staak WJBM. Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol. 1990;23:320–321
  37. Tuyp E, MacKie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol. 1986;14:70–73
  38. Roeder C, von den Driesch P. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol. 1999;9:537–539
  39. Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis. 2006;78:178–180
  40. Geilen CC, Tebbe B, Garcia-Baretls C, Krengel S, Orfanos CE. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol. 1998;138:1101–1102
  41. Arbiser JL, Grossman K, Kaye E, Arndt KA. Use of short-course class I topical glucocorticoid under occlusion for the rapid control of erythrodermic psoriasis. Arch Dermatol. 1994;130:704–706

 Supported by the National Psoriasis Foundation.

 Disclosure: Dr Van Voorhees has received grant support from Amgen, Astellas, and Warner Chilcott. She has been a consultant, advisory board member, or speaker for Amgen, Centocor, Connetics, Genentech, and Warner Chilcott and a drug safety monitoring board member for Synta. She is a major stockholder in Merck. Dr Hsu has been a consultant for Abbott, Amgen, Biogen Idec, Centocor, and Genentech. She has been a clinical investigator for Amgen and Centocor. Dr Korman has been a consultant, investigator, or speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, UCB Pharma, Stiefel, Triax, Pharmaderm, Medicis, Novartis, and Warner Chilcott. He has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Ms Young has served on the advisory board or been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Bebo is employed by the National Psoriasis Foundation. The foundation receives unrestricted financial support from Abbott, Centocor, Amgen, Wyeth, Genentech, Astellas, Stiefel, Galderma, Warner Chilcott, and Photomedix. Dr Rosenbach has no conflicts of interest to declare.

 Consensus: The medical board of the National Psoriasis Foundation reviewed and endorsed this manuscript by a majority vote.

PII: S0190-9622(09)00690-2

doi: 10.1016/j.jaad.2009.05.048

Journal of the American Academy of Dermatology
Volume 62, Issue 4 , Pages 655-662 , April 2010

Article Tools

* Image Usage & Resolution